Current approaches to the diagnosis and treatment of amyloidosis

Taylor MS, Sidiqi H, Hare J, Kwok F, Choi B, Lee D, Baumwol J, Carrol AS, Vucic S, Neely P, Korczyk D, Thomas L, Mollee P, Stewart G, Gibbs SDJ

Internal Medicine Journal 2022; 52 (12): 2046-2067

The epidemiology of amyloidosis in Queensland, Australia

Wisniowski B, McLeod DSA, Adams R, Harvey Y, Brown I, McGuire L, Armes J, Mollee P.

British Journal of Haematology 2019 Sep;186(6):829-836.

99mTechnetium-pyrophosphate SPECT/CT with novel semiautomated quantification has excellent diagnostic accuracy for detecting cardiac transthyretin amyloidosis

Brown S, Kwok F, Evans S, Geenty P, Thomas L, Larcos G, Farlow

Nuclear Medicine Communications 2025 Mar 12

A GP guide to amyloidosis

Yap KG and Mollee P

AusDoc 30th November 2024

Daratumumab-based Treatment for Immunoglobulin Light-Chain Amyloidosis

Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P, Venner C, Lu J, Schönland S, Gatt M, Suzuki K, Kim K, Cibeira M, Beksac M, Libby E, Valent J, Hungria V, Wong S, Rosenzweig M, Bumma N, Huart A, Dimopoulos M, Bhutani D, Waxman A, Goodman S, Zonder J, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoe E, Ahmadi T, Tran N, Qin X, Vasey S, Tromp B, Schecter J, Weiss B, Zhuang S, Vermeulen J, Merlini G, Comenzo RL

New England Journal of Medicine 2021;385(1):46-58

Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines

Sanchorawala V, Boccadoro M, Gertz M, Hegenbart U, Kastritis E, Landau H, Mollee M, Wechalekar A and Giovanni Palladini

Amyloid, 2022 Mar;29(1):1-7.

Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group.

Wechlekar AD, Cibeira MT, Gibbs SD, Jaccard A, Kumar S, Merlini G, Palladini G, Sanchorawala V, Schonland S, Venner C, Boccadoro M, Kastritis E.

Amyloid 2023 Mar;30(1):3-17.

Optimal care pathway for people with AL amyloidosis

2024 Australia-New Zealand Expert Consensus Statement on Cardiac Amyloidosis

Bart NK, Fatkin D, Gunton J, Hare JL, Korczyk D, Kork F, Lam K, Russell D, Sidiqi MH, Sutton, Gibbs SDJ, Mollee P and Thomas L

Heart Lung Circ 2024 Apr;33(4):420-442

Transthyretin Cardiac Amyloidosis in Australia and New Zealand – A Multi-Site Snapshot for 2022

Geenty P, Davidson N, Gorrie N, Bart N, Baumwol J, Sutton T, Kwok F, Hare JL, Peck KY, Korczyk D, Gibbs SDJ, Thomas L

Heart Lung Circ 2025 Jan;34(1):48-57.

Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy

Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs SDJ, Grogan M, Hanna M, Hoffman J, Masri A, Maurer MS, Nativi Nicolau J, Obici L, Poulsen SH, Rockhold F, Shah KB, Soman P, Garg J, Chiswell K, Xu H, Cao X, Lystig T, Sinha U and Fox JC

New England Journal of Medicine 2024;380:132-142